Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6325 Neoplasms 5305 Prostatic Neoplasms 2944 Carcinoma, Non-Small-Cell Lung 2685 Colorectal Neoplasms 2642 Lung Neoplasms 2243 Multiple Myeloma 1647 Lymphoma 1590 Neoplasm Metastasis 1538 Leukemia, Myeloid, Acute 1524 Melanoma 1477 Pancreatic Neoplasms 1459 Ovarian Neoplasms 1412 Leukemia 1385 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1272 Head and Neck Neoplasms 1262 Lymphoma, Non-Hodgkin 1221 Colonic Neoplasms 1151 Carcinoma, Hepatocellular 1125 Stomach Neoplasms 1116 Leukemia, Lymphocytic, Chronic, B-Cell 1088 Brain Neoplasms 1040 Lymphoma, Follicular 975 Rectal Neoplasms 972 Recurrence 964 Uterine Cervical Neoplasms 915 Glioblastoma 911 Carcinoma, Renal Cell 874 Lymphoma, Large B-Cell, Diffuse 847 Hodgkin Disease 772

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡